Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | GRIN2D known ✓ | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B known ✓ | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 known ✓ | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A known ✓ | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B known ✓ | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C known ✓ | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 2/20 | 0.42 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31138645 | 1.00 | LMNA (0.48) | LMNAGAAALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL1259553 | 0.98 | LMNA (0.47) | LMNAGAAALDH1A1POLBTDP1 | |
| SCHEMBL29712527 | 0.98 | LMNA (0.50) | LMNAGAAALDH1A1POLBTDP1 | |
| SCHEMBL958496 | 0.98 | LMNA (0.50) | LMNAGAAALDH1A1POLBTDP1 | |
| SCHEMBL17558530 | 0.82 | PARP1 (0.43) | LMNAGAAALDH1A1TDP1GRIN2D | |
| Hydrochloric Acid SCHEMBL27788451 | 0.82 | LMNA (0.37) | LMNAGAAALDH1A1POLBTDP1 | |
| SCHEMBL6208835 | 0.80 | LMNA (0.38) | LMNAGAAALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL5168765 | 0.79 | LMNA (0.58) | LMNAGAAALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL1267047 | 0.79 | LMNA (0.58) | LMNAGAAALDH1A1POLBTDP1 | |
| Hydrochloric Acid SCHEMBL4002566 | 0.79 | LMNA (0.58) | LMNAGAAALDH1A1POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117835716-A | Passivation layer material and preparation method thereof, perovskite solar cell and preparation method thereof | 旗滨新能源发展(深圳)有限责任公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-106632075-B | A kind of synthetic method of 2,4,6- triphenyls pyridine derivatives | 安徽师范大学 | 2018-10-30 | — | — | CN | disclosed |
| CN-106632106-A | Synthetic method of asymmetric 1,2,4-triazole derivatives | 安徽师范大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-106632075-A | Synthesis method for 2,4,6-triphenyl pyrimidine derivative | 安徽师范大学 | 2017-05-10 | — | — | CN | disclosed |
| CN-102712799-B | Polyester resin composition | FUJIFILM CORP | 2014-06-04 | — | — | CN | disclosed |
| CN-102712799-A | Polyester resin composition | FUJIFILM CORP | 2012-10-03 | — | — | CN | disclosed |
| CN-102510861-A | New triazine derivative, ultraviolet absorber, and resin composition | FUJIFILM CORP | 2012-06-20 | — | — | CN | disclosed |
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | CYTRX CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-7745465-B2 | Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof | CYTRX CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | HICKEY DEIDRE MARY BERNADETTE | 2010-06-10 | — | — | US | disclosed |
| US-7148239-B2 | Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof | CYTRX CORPORATION (US) | 2006-12-12 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| EP-1417202-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-05-12 | — | — | EP | disclosed |
| WO-2002079186-A2 | AMINOPIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-10 | — | — | WO | disclosed |
| CN-1079789-C | Hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | BIOREX KUTATO FEJLESZTOE KFT (HU) | 2002-02-27 | — | — | CN | disclosed |
| CN-1151728-A | Hydroximic acid derivatives, pharmaceutical compositions containing them and process for preparing same | BIOREX KUTATO FEJLESZTOE KFT (HU) | 1997-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267711-A1 | METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF | HSPE1, HSF1, HSP90AB2P | GAA 380/4885GRIN2D 4874/4885GRIN3B 4821/4885 |
| US-20100144765-A1 | 5,6-TRIMETHYLENEPYRIMIDIN-4-ONE COMPOUNDS | PLA2G4A, PLA2G4B, PLA2G1B | GAA 797/4885GRIN2D 3799/4885GRIN3B 2747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.